What are the current ASCCP (American Society for Colposcopy and Cervical Pathology) guidelines for management of high‑risk human papillomavirus (HPV) infection and cervical cancer screening across different age groups and special populations?

ASCCP Guidelines for HPV Management

For average-risk women, begin cervical cancer screening at age 21 with cytology alone every 3 years until age 29, then transition to HPV/cytology cotesting every 5 years (preferred) or cytology alone every 3 years from ages 30-65, and discontinue screening after age 65 with adequate prior negative results. 1, 2, 3, 2, 4

Screening by Age Group

Women Under Age 21

• Do not screen regardless of age of sexual initiation or other risk factors 1, 2, 4

Women Ages 21-29 Years

• Cytology alone every 3 years (conventional Pap or liquid-based cytology) 1, 2, 3, 2
• HPV testing should NOT be used for routine screening in this age group 1, 2, 4
• HPV testing may be used as reflex testing for ASC-US results in women 25-29 years 5
• Rationale: HPV infections are transient in young women (up to 90% clear within 2 years), making routine HPV testing not clinically useful 6

Women Ages 30-65 Years

• Preferred: HPV/cytology cotesting every 5 years 1, 2, 3, 2, 4
• Acceptable alternative: Cytology alone every 3 years 1, 2, 4
• Women with HPV-negative ASC-US should return for screening in 3 years 4

Women Over Age 65

• Discontinue screening if adequate prior negative results: 1, 2, 4
  • 3 consecutive negative cytology tests OR
  • 2 consecutive negative cotests
  • Within the 10-year period before stopping
  • With most recent test within last 5 years
• Exception: Continue screening for at least 20 years (even past age 65) after spontaneous regression or treatment of CIN2, CIN3, adenocarcinoma in situ, or more severe diagnoses 3, 2, 4
• Once discontinued, do not resume for any reason, including new sexual partners 4

Critical Management Principles

Universal Rules

• Annual screening is NOT recommended for any age group by any method 1, 2, 3, 2
• HPV vaccination status does not change screening recommendations - vaccinated women follow same guidelines 2, 4

Management of Abnormal Results (2019 ASCCP Risk-Based Guidelines)

The 2019 ASCCP guidelines shifted to risk-based management using estimated risk of CIN3+ rather than test result alone 7, 8, 9, 10. Key principles:

For Young Women (Ages 21-24):

• Conservative management preferred to avoid overtreatment of lesions likely to regress 5
• CIN 1: Do not treat unless persistent for 2 years 5
• CIN 2: Observation recommended 5
• CIN 3: Treat with diagnostic excisional procedure, but hysterectomy is NOT primary treatment 5
• HSIL cytology: Colposcopy recommended but immediate treatment is not 5

For Women Ages 25-29:

• Reflex HPV testing preferred for ASC-US (though cotesting not used for routine screening) 5
• Risk of cervical cancer begins increasing in this age group 5

For Women Over 65:

• Continue screening if ASC-US present, even if HPV-negative 5

Post-Treatment Surveillance:

• After treatment for CIN2+, require 3 negative HPV tests or cotests at 6,18, and 30 months before returning to 3-year intervals 7
• HPV testing has higher negative predictive value (98%) than negative margins (91%) or cytology (93%) for detecting residual disease 6

Special Populations

Women with Total Hysterectomy

• Discontinue screening if cervix removed AND no history of CIN2+, adenocarcinoma in situ, or cervical cancer 1, 2, 5
• Women with supracervical hysterectomy: Follow standard screening recommendations 3, 2

High-Risk Populations (Guidelines Do NOT Apply)

These women require more intensive surveillance per specialized guidelines 1, 2, 3, 2:

• History of cervical cancer
• In utero diethylstilbestrol exposure
• HIV-positive (follow 2021 Opportunistic Infections guidelines) 7
• Immunocompromised (organ transplant, chemotherapy, chronic corticosteroids)

For HIV-positive/immunosuppressed: Test twice in first year after diagnosis, then annually 3

Pregnant Women

• Management of ASC-US/LSIL same as non-pregnant, but colposcopy can be deferred until ≥6 weeks postpartum 6
• Colposcopy and directed biopsies safe when needed to rule out invasion 6
• Endocervical curettage is unacceptable in pregnancy 6
• Treatment unacceptable without cancer confirmation due to hemorrhage/fetal loss risk 6
• For CIN2,3: Repeat cytology/colposcopy every 12 weeks; rebiopsy only if worsening or cytology suggests invasion 6
• High postpartum regression rates: CIN 1 (36%), CIN 2,3 (48-70%) 6

Implementation Updates

The 2019 ASCCP guidelines represent a paradigm shift to risk-based management that incorporates current AND prior test results for personalized risk estimation 8, 9. This approach:

• Uses HPV-based testing as foundation for risk estimation
• Applies "equal management for equal risk" principle
• Balances benefits and harms
• Adapts to decreasing CIN3+ risk as HPV-vaccinated cohorts reach screening age 8

Recent clarifications through 2023 7:

• Unsatisfactory cytology management revised
• For patients ≥25 screened with cytology only, follow 2012 guidelines
• Specific guidance for patients with recommended but incomplete colposcopy
• Clarification on post-treatment surveillance intervals

The ASCCP has endorsed the shift toward primary HPV screening as recommended by ACS 2020 guidelines, though recognizes barriers to widespread adoption including implementation challenges and populations underrepresented in trials 11. Most importantly, any cervical cancer screening is better than none - focus on reaching underscreened/unscreened populations 11.